Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cardiff Oncology Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CRDF
Nasdaq
8731
https://cardiffoncology.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cardiff Oncology Inc
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
- Apr 25th, 2024 8:05 pm
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
- Apr 8th, 2024 8:05 pm
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
- Mar 6th, 2024 9:05 pm
Cardiff Oncology Full Year 2023 Earnings: Beats Expectations
- Mar 3rd, 2024 1:40 pm
Cardiff Oncology Inc (CRDF) Reports Q4 and Full Year 2023 Financial Results
- Mar 1st, 2024 3:12 pm
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
- Feb 29th, 2024 9:07 pm
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
- Feb 29th, 2024 9:06 pm
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
- Feb 29th, 2024 9:05 pm
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
- Feb 26th, 2024 1:00 pm
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
- Feb 22nd, 2024 1:00 pm
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
- Jan 17th, 2024 3:30 pm
Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference
- Nov 20th, 2023 9:05 pm
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
- Nov 2nd, 2023 8:05 pm
We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
- Oct 31st, 2023 3:40 pm
Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update
- Oct 26th, 2023 8:05 pm
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy
- Sep 26th, 2023 8:05 pm
Cardiff Oncology to Present at Upcoming Investor Conferences in September
- Sep 5th, 2023 12:00 pm
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update
- Aug 9th, 2023 8:05 pm
Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship
- Aug 7th, 2023 8:05 pm
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Jul 24th, 2023 9:09 pm
Scroll